Gamcemetinib

DB21624InvestigationalSmall molecule

Gamcemetinib is a small molecule drug. The usage of the INN stem '-tinib' in the name indicates that Gamcemetinib is a tyrosine kinase inhibitor. Gamcemetinib is under investigation in clinical... Gamcemetinib is under investigation in clinical trial NCT04947579 (A Study of CC-99677 in Participants With Active Ankylosing Spondylitis).

Mechanism: Pharmacologically active on MAP kinase-activated protein kinase 2
Curator reviewed
Formula / weight: C₂₂H₂₀ClN₅O₃S · 469.94 g/mol (avg)
Code names: BMS-986371 · CC-99677

Resolves to

Compound

UNIIOS2IR8TV1OCAS1887069-10-4ChEMBLCHEMBL5314585ChEBI759283PubChem118936948

Structure

InChIKeyPYOQIOLRFIRRSO-LLVKDONJSA-NSMILESCCOCC1=CN=C(Cl)N=C1OC1=NC2=C(C=C1)C1=C(SC3=C1NC[C@@H](C)NC3=O)C=C2

Targets

P49137MAPKAPK2

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Gamcemetinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account